

Attorney Docket : **ANVIL.001BNP1**
Appl. No. : **10/584,968**
Filed : **June 30, 2006**

AMENDMENTS TO THE CLAIMS

1.-13. (Canceled)

14. (Original) A prosthesis for placement at an opening from a main body lumen to a branch body lumen, the prosthesis comprising:

 a radially expandable support, the support configured to be deployed in at least a portion of the branch body lumen;

 at least one frond extending from an end of the support and configured to be positioned across the Os and into the main body lumen; and

 at least one circumferential link connected to the frond, the circumferential link spaced axially apart from the support.

15. (Original) The prosthesis as in Claim 14, wherein the circumferential link is expandable from a first, reduced diameter to a second, enlarged diameter.

16. (Original) The prosthesis as in Claim 14, wherein the at least one frond includes at least three fronds.

17. (Original) The prosthesis as in Claim 14, wherein the at least one frond comprises a helical configuration.

18. (Original) The prosthesis as in Claim 17, comprising a plurality of helical fronds.

19. (Original) The prosthesis as in Claim 14, wherein at least a portion of the frond comprises a lubricous coating.

20. (Original) The prosthesis as in Claim 14, wherein the support is on a first end of the frond, and the circumferential link is on a second end of the frond.

21. (Original) The prosthesis as in Claim 14, wherein the circumferential link is radiopaque.

Attorney Docket : ANVIL.001BNP1
Appl. No. : 10/584,968
Filed : June 30, 2006

22. (Original) The prosthesis as in Claim 21, wherein the circumferential link has a greater radiopacity than the frond.

23. (Original) The prosthesis as in Claim 14, comprising an endothelial cell ingrowth surface.

24. (Original) The prosthesis as in Claim 14, comprising a non thrombogenic surface.

25.-29. (Canceled)

30. (Currently Amended) The prosthesis as in Claim 14, wherein the ~~plurality of fronds~~ at least one frond includes at least three fronds.

31. (Currently Amended) The prosthesis as in Claim 14, wherein the ~~plurality of fronds~~ at least one frond comprises a helical configuration.

32. (Previously Presented) The prosthesis as in Claim 31, comprising a plurality of helical fronds.

33. (Currently Amended) The prosthesis as in Claim 14, wherein at least a portion of the ~~plurality of fronds~~ at least one frond comprises a lubricous coating.

34. (Previously Presented) The prosthesis as in Claim 14, comprising an endothelial cell ingrowth surface.

35. (Previously Presented) The prosthesis as in Claim 14, comprising a non thrombogenic surface.

36. (Currently Amended) The prosthesis as in Claim 14, wherein the at least one frond comprises a plurality of fronds and wherein the further comprising a circumferential link that connects to each of the plurality of fronds.

Attorney Docket : **ANVIL.001BNP1**
Appl. No. : **10/584,968**
Filed : **June 30, 2006**

37. **(Previously Presented)** The prosthesis as in Claim 36, wherein at least a portion of the radially expansible support comprises a drug coating, and at least a portion of the fronds and the circumferential link are without a drug coating.

38. **(Previously Presented)** The prosthesis as in Claim 37, wherein the drug coating is configured to produce at least one of a controlled drug release rate, a constant drug release rate, bi-modal drug release rate or a controlled concentration of drug proximate a target vessel wall.

39. **(Previously Presented)** The prosthesis as in Claim 37, wherein the drug is one of an anti-cell proliferative, anti cell migration, anti-neo plastic, anti inflammatory drug.

40. **(Previously Presented)** The prosthesis as in Claim 37, wherein the drug is configured to reduce an incidence or amount of restenosis.

41. **(Previously Presented)** The prosthesis as in Claim 37, wherein the drug coating includes a first coating and a second coating.

42. **(Previously Presented)** The prosthesis as in Claim 41, wherein the first coating is configured to produce a first drug release rate and the second coating is configured to produce a second drug release rate.

43. **(Previously Presented)** The prosthesis as in Claim 36, wherein the circumferential link is expandable from a first, reduced diameter to a second, enlarged diameter.

44. **(Previously Presented)** The prosthesis as in Claim 36, wherein the support is on a first end of at least one of the fronds, and the circumferential link is on a second end of at least one of the fronds.

45. **(Currently Amended)** The prosthesis as in Claim [[36]]14, wherein the circumferential link is radiopaque.

Attorney Docket : **ANVIL.001BNP1**
Appl. No. : **10/584,968**
Filed : **June 30, 2006**

46. **(Currently Amended)** The prosthesis as in Claim [[36]]14, wherein the circumferential link has a greater radiopacity than the at least one frond.

47. **(New)** The prosthesis of Claim 14, wherein the prosthesis includes a drug incorporated into a polymer matrix.

48. **(New)** The prosthesis of Claim 14, wherein the prosthesis includes a laminate structure and a drug incorporated into the laminate structure.

49. **(New)** The prosthesis of Claim 48, wherein the laminate structure includes a base layer and a top layer, the drug being incorporated into at least one of the top layer and the base layer.

50. **(New)** The prosthesis of Claim 14, wherein the prosthesis includes one or more reservoirs configured to be loaded with a drug.

51. **(New)** The prosthesis of Claim 50, wherein the prosthesis includes one or more drugs in the one or more reservoirs.